Intrinsiqq
Bioforce Nanosciences Holdings Inc. logo

Bioforce Nanosciences Holdings Inc. Quality Score

BFNH

Compare
Quality40

Valuation is the primary weakness (avg 0/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-700.0x

Negative earnings, no valuation support

Revenue Growth
100/100
98.7%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
130.0%

Heavy dilution above 5%

Margin Trend
100/100
+432.9pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$31696

Net cash position, no leverage concern

2017
$14325
$0.00
2018
$29392
$0.00
2019
$52895
$0.00
TTM
$31696
$0.00
CashDebt
Return on Capital
0/100
-95.4%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Bioforce Nanosciences Holdings (BFNH) quality: score, margins and returns

Bioforce Nanosciences Holdings (BFNH) scores 40/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 5 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Bioforce Nanosciences Holdings (BFNH) a high-quality business?+

Bioforce Nanosciences Holdings scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a mixed business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Bioforce Nanosciences Holdings's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BFNH's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Bioforce Nanosciences Holdings scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 9 Nov 2026, covering the period ending 31 Dec 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Laboratory Analytical Instruments · Pick stocks to compare with BFNH

CompareIntrinsic value
YBGJYubo International Biotech Limited
$0.01+0.00%10
NVNOEnVVeno Medical Corporation
$5.25-5.75%10
STMEStimcell Energetics Inc.
$0.24+0.00%0
DRORDror Ortho-Design Inc.
$0.00+0.00%40
ODYYOdyssey Group International Inc.
$0.01-7.14%10
HCILHongchang International Co. Ltd.
$0.00+0.00%10
RDGLVivos Inc.
$0.04-2.68%40
PAVMPAVmed Inc.
$1.14-5.42%35

Spot a number that looks wrong? Check it in BFNH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BFNH

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.